HighVista Strategies’s Structure Therapeutics GPCR Stock Holding History

HighVista Strategies’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.97M	Sell	123,909 -69,092	-36%	-$4.73M	1.65%	9
2025 Q4	$13.4M	Sell	193,001 -43,235	-18%	-$1.77M	3.46%	2
2025 Q3	$6.61M	Buy	236,236 +149,615	+173%	+$2.98M	1.62%	15
2025 Q2	$1.8M	Buy	86,621 +69,060	+393%	+$1.52M	0.66%	51
2025 Q1	$304K	Hold	17,561	–	–	0.12%	139
2024 Q4	$476K	Sell	17,561 -14,157	-45%	-$502K	0.18%	123
2024 Q3	$1.39M	Sell	31,718 -3,410	-10%	-$132K	0.48%	88
2024 Q2	$1.38M	Sell	35,128 -2,316	-6%	-$95.1K	0.5%	74
2024 Q1	$1.6M	Sell	37,444 -37,388	-50%	-$1.58M	0.57%	61
2023 Q4	$3.05M	Hold	74,832	–	–	1.11%	27
2023 Q3	$3.77M	Buy	+74,832	New	+$2.41M	1.75%	11

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

HighVista Strategies's GPCR Position: Q1 2026 in Review

HighVista Strategies reduced its Structure Therapeutics (GPCR) stake by 36% in Q1 2026, selling an estimated $4.73M and leaving 123,909 shares worth $5.97M. The position accounts for 1.65% of the portfolio, ranked #9.

HighVista Strategies first reported a position in GPCR in Q3 2023 and has held it in 11 quarters since. The position peaked at $13.4M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

HighVista Strategies held 123,909 shares of Structure Therapeutics worth $5.97M as of Q1 2026.
HighVista Strategies sold 69,092 Structure Therapeutics shares in Q1 2026, an estimated $4.73M.
Structure Therapeutics made up 1.65% of HighVista Strategies's portfolio in Q1 2026, its #9 holding.
HighVista Strategies first reported a position in Structure Therapeutics in Q3 2023 and has held it in 11 quarters since.
HighVista Strategies's Structure Therapeutics position peaked at $13.4M in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.